Actualités sur Santé / Médecine

SYMETIS SA

2

Symetis and Boston Scientific reach USD 435 million purchase agreement

Debiopharm International SA

Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Lausanne (ots) - Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group(TM) (www.debiopharm.com), announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically ...

Debiopharm International SA

Debiopharm Group[TM] grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -

Lausanne (ots) - Debiopharm Group[TM] (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture ...